论文部分内容阅读
目的观察百令胶囊联合左卡尼汀对维持性血液透析(MHD)患者C反应蛋白(CRP)、白细胞介素6(IL-6)、白蛋白(ALB)的影响。方法按随机数字表法将62例MHD治疗的慢性肾衰竭患者分为治疗组和对照组各31例。对照组进行2周5次的血液透析治疗,每次透析时间均为4h,同时据病情予降压、降糖、纠正贫血等慢性肾衰竭一体化治疗。治疗组在对照治疗的基础上加用百令胶囊联合左卡尼汀治疗。比较2组患者治疗前、治疗5个月后CRP、IL-6和血清ALB等指标变化情况。结果 2组治疗前血清CRP、IL-6及ALB水平差异无统计学意义(P>0.05);治疗5个月后,对照组CRP、IL-6及血清ALB与治疗前比较差异无统计学意义(P>0.05),治疗组CRP、IL-6较治疗前明显降低,血清ALB较治疗前明显升高,差异均有统计学意义(P<0.05);治疗组CRP、IL-6显著低于对照组,血清ALB水平显著高于对照组,差异均有统计学意义(P<0.05)。结论百令胶囊联合左卡尼汀治疗MHD患者可以降低CRP、IL-6,升高血清ALB,有效改善患者微炎性反应状态,改善营养状况,提高生活质量。
Objective To observe the effects of Bailing capsule combined with levocarnitine on C-reactive protein (CRP), interleukin-6 (IL-6) and albumin (ALB) in maintenance hemodialysis (MHD) patients. Methods 62 patients with chronic renal failure treated by MHD were divided into treatment group (n = 31) and control group (n = 31) according to random number table method. The control group was treated with hemodialysis twice a week for 5 times. Each dialysis time was 4 hours. At the same time, according to the condition, blood pressure, hypoglycemic, anemia and other chronic renal failure were integrated. The treatment group based on the control treatment plus Bailing capsule combined with levocarnitine treatment. The changes of CRP, IL-6 and serum ALB in two groups before treatment and after 5 months of treatment were compared. Results There was no significant difference in serum CRP, IL-6 and ALB levels between the two groups before treatment (P> 0.05). After 5 months of treatment, there was no significant difference in CRP, IL-6 and serum ALB between the two groups (P> 0.05). The levels of CRP and IL-6 in the treatment group were significantly lower than those before treatment, and the level of serum ALB was significantly higher than that before treatment (P <0.05). The CRP and IL-6 levels in the treatment group were significantly lower than those before treatment The level of serum ALB in the control group was significantly higher than that in the control group (P <0.05). Conclusion Bailing capsule combined with levocarnitine can reduce CRP, IL-6 and increase serum ALB in patients with MHD, effectively improve the patient’s micro-inflammatory response status, improve nutritional status and improve quality of life.